ClinicalTrials.gg
RecruitingNCT07636811Updated Oct 13, 2026

A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

A Phase 2 interventional study of Mivelsiran and Placebo in Down Syndrome-Associated Alzheimer's Disease (DS-AD), sponsored by Alnylam Pharmaceuticals. Recruiting at 10 sites in 2 countries. Open to participants aged 40 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Alnylam Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 13, 2026Study completion moved9 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
40 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Down Syndrome with a site in Spain — 9 open to participants now, 9 under way, 1 of them phase 3. Down Syndrome · Spain.

Planned enrollment
9th of 18
58 · median 58
Started
2026
with 1 other
Phase 2
4 of 36
2 open now
Registered
36th of 36
by date
Lead sponsor
1 of 36
Alnylam Pharmaceuticals

Among the 36 studies in Down Syndrome with a site in Spain, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 36th registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 100 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

9 of the 36 studies in Down Syndrome with a site in Spain are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 75 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 58 (77%) stop at 75 or younger; 61 take children under 18; 19 take healthy volunteers.

This study: 40 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Down Syndrome with a site in Spain, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the effect of mivelsiran in adult participants with early-stage DS-AD and to characterize the safety, tolerability, and pharmacodynamics (PD) of mivelsiran. The study will be conducted over 2 periods: a 24-month double-blind period and an optional 12-month open-label treatment extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 39 months.

03

Conditions studied

  • Down Syndrome-Associated Alzheimer's Disease (DS-AD)

Browse trials for

Keywords

  • Alzheimer's; DS-AD; Down Syndrome; ALZ
04

Who can participate

Ages eligible
40 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Down-Syndrome (DS) associated with trisomy 21
  • Positive amyloid PET scan
  • Cognitively stable in the opinion of the investigator
  • Seizures must be well controlled with no occurrence of seizures in the 6 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • Has severe intellectual disability (ID)
  • Has a history of DS regression disorder
  • Has (ALT) or aspartate aminotransferase (AST) >2× (ULN) at Screening
  • Has estimated (eGFR) \<45 mL/min/1.73m\^2 at Screening
  • Has recently received an agent
  • Has had treatment with amyloid-targeting antibody
  • Comorbidities such as obstructive sleep apnea and hypothyroidism that are not well controlled

Note: other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Mivelsiran (Treatment Group A)

    Participants will be administered multiple low doses of mivelsiran.

    Drug: Mivelsiran

  • Experimental
    Mivelsiran (Treatment Group B)

    Participants will be administered multiple high doses of mivelsiran.

    Drug: Mivelsiran

  • Placebo comparator
    Placebo (Treatment Group C)

    Participants will be administered multiple doses of placebo.

    Drug: Placebo

Interventions

  • Mivelsiran will be administered intrathecally

    Also known as: ALN-APP

  • DrugPlacebo

    Placebo will be administered intrathecally

06

What researchers measure

Primary outcomes

  1. Double-Blind Period: Change from baseline in brain amyloid burden measured in centiloids (CLs)

    Time frame: Up to 24 months

Secondary outcomes

  1. Double-Blind Period: Change from baseline in APP protein concentration in cerebrospinal fluid (CSF)

    Time frame: Up to 24 months

  2. Double-Blind Period: Change from baseline in the concentration of amyloid beta proteins in CSF

    Time frame: Up to 24 months

  3. Double-Blind Period: Change from baseline in the concentration of tau proteins in plasma

    Time frame: Up to 24 months

  4. Double-Blind Period: Change from baseline on a cognitive scale

    Time frame: Up to 24 months

  5. Double-blind Period and Open-label Extension (OLE) Period: Frequency of adverse events (AEs)

    Time frame: Up to 36 months

07

Study locations

10 of 10 sites recruiting
  • Clinical Trial Site
    Maitland, Florida 32751, United States
    Recruiting
  • Clinical Trial Site
    Naples, Florida 34105, United States
    Recruiting
  • Clinical Trial Site
    Indianapolis, Indiana 46037, United States
    Recruiting
  • Clinical Trial Site
    St Louis, Missouri 63110, United States
    Recruiting
  • Clinical Trial Site
    Barcelona, Spain
    Recruiting
  • Clinical Trial Site
    Dos Hermanas, Spain
    Recruiting
  • Clinical Trial Site
    Madrid, Spain
    Recruiting
  • Clinical Trial Site
    Pamplona, Spain
    Recruiting
  • Clinical Trial Site
    Seville, Spain
    Recruiting
  • Clinical Trial Site
    Valencia, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for May 2030, 45 months after the start.

Of 21 phase 2 interventional studies under Down Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 61. This study's planned 45 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jun 9, 2026
StartActual
Aug 17, 2026
Primary completionEst.
May 18, 2030
CompletionEst.
Jul 30, 2031
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 2 sites removed
Show 9 added (5 Spain, 4 United States)
  • Clinical Trial Site · Maitland, United States
  • Clinical Trial Site · Naples, United States
  • Clinical Trial Site · Indianapolis, United States
  • Clinical Trial Site · St Louis, United States
  • Clinical Trial Site · Barcelona, Spain
  • Clinical Trial Site · Dos Hermanas, Spain
  • Clinical Trial Site · Madrid, Spain
  • Clinical Trial Site · Pamplona, Spain
  • Clinical Trial Site · Valencia, Spain
Show 2 removed
  • Clinical Study Site · Maitland, United States
  • Clinical Study Site · Naples, United States
Oct 13, 2026
Study completion
Jul 23, 2031→Jul 30, 2031
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    9 sites added, 2 sites removed
    Show 9 added (5 Spain, 4 United States)
    • Clinical Trial Site · Maitland, United States
    • Clinical Trial Site · Naples, United States
    • Clinical Trial Site · Indianapolis, United States
    • Clinical Trial Site · St Louis, United States
    • Clinical Trial Site · Barcelona, Spain
    • Clinical Trial Site · Dos Hermanas, Spain
    • Clinical Trial Site · Madrid, Spain
    • Clinical Trial Site · Pamplona, Spain
    • Clinical Trial Site · Valencia, Spain
    Show 2 removed
    • Clinical Study Site · Maitland, United States
    • Clinical Study Site · Naples, United States
    Study completion Jul 23, 2031→Jul 30, 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07636811
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
Aug 17, 2026
Primary completion
May 18, 2030 (estimated)
Completion
Jul 30, 2031 (estimated)
Last update
Oct 13, 2026

Study contacts

Alnylam Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-ALNYLAM
Alnylam Clinical Trial Information Line
Contact
clinicaltrials@alnylam.com
1-877-256-9526
Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mivelsiran

Start the discussion